Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates
Provided By GlobeNewswire
Last update: Feb 19, 2025
Building on proven targeting of the FHAB domain, Sonnet’s ADC platform offers flexible payload capacity and controllable drug-antibody ratios (DAR)
Read more at globenewswire.comNASDAQ:SONN (2/21/2025, 8:00:02 PM)
1.44
+0.01 (+0.7%)
Find more stocks in the Stock Screener
